Drugs / Human Insulin Inhalation Powder
Human Insulin Inhalation Powder
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00437112 | Feb 2007 → May 2008 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00391209 | Oct 2006 → May 2008 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00330473 | Jun 2006 → May 2008 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00127634 | Jul 2005 → May 2008 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Human Insulin Inhalation Powder | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00330473 ↗ |
| Known as | AIR Inhaled Insulin | “A study to compare Human Inhalation Powder (also known as AIR® Inhaled Insulin) (AIR® is a registered trademark of Alkermes, Inc.)with insulin glargine injections in patients...” NCT00437112 ↗1“starting with a fixed dose of HIIP (also known as AIR® Inhaled Insulin)” NCT00391209 ↗ |
| Known as | HIIP | “A Phase 3, Open-Label, Parallel-Group Study to Compare Two Dosing Algorithms for Preprandial Human Insulin Inhalation Powder (HIIP) in Insulin-Naive Patients With Type 2...” NCT00391209 ↗ |
| Known as | Human Inhalation Powder | “A study to compare Human Inhalation Powder (also known as AIR® Inhaled Insulin) (AIR® is a registered trademark of Alkermes, Inc.)with insulin glargine injections in patients...” NCT00437112 ↗ |
| Route | Inhaled | “patient specific dose, inhaled, before meals, 24 months, up to 36 months” NCT00127634 ↗ |